2026年11月4日星期三
M
Panorama Universal
Notícias globais
Nintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei Asia

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease

Fonte 柳叶刀 LancetHá 11 dias
Resumo do conteúdo

Sickle cell disease is the most common haemoglobinopathy, affecting more than 7 million people worldwide.1 Despite substantial morbidity and mortality, access…

Este site fornece apenas o título e o índice do resumo; o conteúdo completo e os direitos autorais pertencem ao publicador original. Clique no link do texto original para ler.

Ir para o texto original
Canal de origem
Saúde
Região de origem
Reino Unido
Idioma do texto original
English
Número do item
health-7abf72c7

Comments 0 comments

No comments yet. Be the first.

[Comment] Mitapivat in the RISE UP trial: a new therapy for sickle cell disease · Panorama Universal